The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isReached phase 1 in humans, and no further.
- What to watchFatigue, cold intolerance and weight gain from a low thyroid signal.
How GC-1 works
Thyroid-hormone receptor-β (TRβ1) selective agonist — drives hepatic lipid clearance and metabolic rate while largely sparing TRα1, the receptor isoform that carries T3's effects on the heart.
There are two thyroid hormone receptors and they sit in different organs. That is the entire design of this molecule.
And the cardiac half of that claim has a named gene behind it, which almost nobody quotes. GC-1 produced better triglyceride-lowering and similar cholesterol-lowering than T3 — and then the separation: T3, but not GC-1, increased heart rate, and T3 raised HCN2 messenger RNA. HCN2 is a subunit of the hyperpolarization-activated pacemaker channel that sets the sinoatrial firing rate.
- Oral
On the goal map: Thyroid & metabolic rate (Energy & fatigue)
Research on GC-16 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Reached phase 1 in humans, and no further. As sobetirome it went through phase 1 trials for hypercholesterolemia without obvious harmful side effects, and development stopped there: no phase 2 was ever run (Lammel Lindemann & Webb 2016).
Later work repurposed the scaffold for X-linked adrenoleukodystrophy, using a CNS-penetrant prodrug in mice. The two human trials registered in that disease (NCT01787578, NCT03196765) were both withdrawn before enrolling — a rare-disease application quite unrelated to how it is sold in the research market.
Correlative data
Research-market use for fat loss, on the reasoning that it delivers thyroid hormone's metabolic effects without the cardiac ones. Reported experience includes suppression of the thyroid axis, which is what any thyroid receptor agonist does and is the thing people underestimate.
How the mechanism reads
A selective thyroid hormone receptor beta agonist. The distinction carries the whole rationale: TRβ predominates in liver and drives cholesterol clearance and metabolic rate, while TRα predominates in heart and mediates the tachycardia and arrhythmia that make T3 dangerous for weight loss.
MechanisticThe same TRβ logic produced resmetirom, which was approved for MASH in 2024 — so the mechanism is validated in humans, just not in this molecule.
MechanisticSelectivity is relative, not absolute. And the axis suppression happens regardless of selectivity because the pituitary uses TRβ to sense thyroid status.
Mechanistic
Sources
- Scanlan TS. Sobetirome: a case history of bench-to-clinic drug discovery and development.. Heart Fail Rev 2010 · PMID 19002578
- Lammel Lindemann J, Webb P. Sobetirome: the past, present and questions about the future.. Expert Opin Ther Targets 2016 · PMID 26565124
- Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.. Endocrinology 2000 · PMID 10965874
- Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine.. Endocrinology 2004 · PMID 14701670
- Columbano A, Pibiri M, Deidda M, Cossu C, Scanlan TS, Chiellini G, Muntoni S, Ledda-Columbano GM. The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas.. Endocrinology 2006 · PMID 16574785
- Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, Ohlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study.. Lancet Diabetes Endocrinol 2014 · PMID 24731671
GC-1 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Thyroid cancer or an active cancer, since GC-1 drove rat hepatocyte and pancreatic cell proliferation.
- Heart disease or arrhythmia.
- Liver disease, because GC-1 acts in hepatocytes and drove their proliferation in rats.
- Hypothyroidism on thyroid replacement, where TSH suppression is confusing.
- Pregnancy, as thyroid hormone signaling guides fetal brain development.
What’s expected
- LDL cholesterol and triglycerides fall through TR-beta action in the liver.
- A fall in TSH and free T4 from pituitary TR-beta feedback.
- A modest rise in metabolic rate.
Watch for
- Fatigue, cold intolerance and weight gain from a low thyroid signal.
- Palpitations, if thyroid receptor selectivity is imperfect at the heart.
- Upper abdominal swelling or pain.
Labs that tell you it’s working
- TSH: pituitary TR-beta engagement lowers it.
- Free T4: falls as feedback lowers thyroid output, even though you feel fine.
- Free T3: shows how much hormone remains at the tissue.
- Lipid Panel: the LDL and triglyceride drop is the target effect.
Thyroid hormone receptor-beta selective agonist (sobetirome) that spares the cardiac alpha receptor; harms follow from proliferation and axis suppression. PMID 19002578 PMID 14701670
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
GC-1 FAQ4 common questions
- Is GC-1 approved for human use?
- No. GC-1 is a research compound.
- What is GC-1 researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- TSH; Free T4; Free T3; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for GC-1: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



